Deciphex
Founded 2017 · 183 employees on LinkedIn · 10 known investors
Deciphex develops AI-powered platforms to enhance pathology efficiency, including digital image analysis, clinical trial support, and a global network of subspecialty pathologists. The company serves pathologists, pharmaceutical companies, and healthcare systems to improve diagnostic accuracy and drug development outcomes.
Investors · 10
Act Venture CapitalDublin
ACT Venture CapitalDublin · $1.1M – $16.2M
Claret Capital PartnersLondon
Molten VenturesLondon · $2.5M – $63M
Seroba Life SciencesDublin · $540K – $7.6M
Also in the syndicate · 5
Charles River LaboratoriesHBAN Medtech SyndicateIRRUS InvestmentsNextsteps CapitalNovartis
Funding
SEC filings, press & company announcements- Undisclosed amountVenture Debt FundingOct 2025Source ↗
- Undisclosed amountSeries CJan 2025Source ↗
- Undisclosed amountSeries BMay 2022
ACT Venture Capital (lead), Charles River Laboratories, HBAN Medtech Syndicate, IRRUS Investments, Nextsteps Capital, Novartis
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Deciphex do?
- Deciphex develops AI-powered platforms to enhance pathology efficiency, including digital image analysis, clinical trial support, and a global network of subspecialty pathologists. The company serves pathologists, pharmaceutical companies, and healthcare systems to improve diagnostic accuracy and drug development outcomes.
- Who are Deciphex's investors?
- Deciphex's investors include Act Venture Capital, ACT Venture Capital, Claret Capital Partners, Molten Ventures, Seroba Life Sciences.